D-dimer levels correlate with mortality in patients with acute pulmonary embolism:: Findings from the RIETE registry

被引:52
作者
Grau, Enric [1 ]
Maria Tenias, Jose
Jose Soto, Maria
Reyes Gutierrez, Maria
Lecumberri, Ramon
Luis Perez, Jose
Tiberio, Gregorio
机构
[1] Hosp Lluis Alcanyis, Serv Hematol, Valencia, Spain
[2] Hosp Lluis Alcanyis, Serv Med Prevent, Valencia, Spain
[3] Hosp Univ Puerta Mar, Med Interna Serv, Cadiz, Spain
[4] Hosp Ntra Sra Valme, Serv Hematol, Seville, Spain
[5] Univ Navarra Clin, Serv Hematol, Pamplona, Spain
[6] Hosp Univ Laguna, Serv Angiol & Cirugia Vasc, Tenerife, Spain
[7] Hosp Virgen Camino, Med Interna Serv, Pamplona, Spain
关键词
pulmonary embolism; D-dimer; mortality; bleeding; recurrence; anticoagulant therapy;
D O I
10.1097/01.CCM.0000277044.25556.93
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Object: Few studies have addressed the prognostic implications of D-dimer in patients with pulmonary embolism. The aim of this study was to investigate the correlation between D-dimer levels and mortality in patients with pulmonary embolism. Design: Observational study. Setting: Hospitals participating in the Registro Informatizado de la Enfermedad Tromboembolica (RIETE). Patients: A total of 588 consecutive patients with symptomatic pulmonary embolism who were included in the RIETE between March 2001 and December 2004. Interventions: Quantitative D-dimer measurement was performed on admission using an automated latex agglutination test (IL Test D-dimer). All patients underwent clinical follow-up for 3 months. Measurements and Main Results: Overall mortality rate was 10.5%. The cause of death was pulmonary embolism in 18 patients (3.0%), fatal bleeding in one patient (0.2%), and other causes in 43 patients (7.3%). There were 28 (4.8%) nonfatal venous thromboembolism recurrences and 35 (6.0%) nonfatal bleeding episodes. The incidence of D-dimer 500-2499 ng/mL, D-dimer 2500-4999 ng/mL, and D-dimer >= 5000 ng/mL was 47.8%, 26.0%, and 20.4%, respectively. Compared with patients with D-dimer 500-2499 ng/mL, the relative risk (odds ratio) of overall mortality was 1.91 (95% confidence interval 0.91-4.09) and 2.94 (95% confidence interval 1.42-6.25) in patients with D-dimer 2500-4999 ng/mL and D-dimer >= 5000 ng/mL, respectively (p =.032). Patients with D-dimer a:5000 ng/mL showed higher risk of death from fatal pulmonary embolism (odds ratio 4.4, 95% confidence interval 0.5-33.0) than death from other causes (odds ratio 2.1, 95% confidence interval 0.7-6.0). Elevated D-dimer levels were associated with more severe disease, as assessed by clinical features. Conclusions: In patients who present with pulmonary embolism, D-dimer concentration is an independent predictive factor associated with all-cause and pulmonary embolism-related death. D-dimer >= 5000 ng/mL occurs in about one in five patients and is associated with a 2.9-fold increased risk of overall mortality. These results suggest that D-dimer quantification could be a useful biomarker and help determine initial therapies.
引用
收藏
页码:1937 / 1941
页数:5
相关论文
共 25 条
[1]   Validation of a model to predict adverse outcomes in patients with pulmonary embolism [J].
Aujesky, D ;
Roy, PM ;
Le Manach, CP ;
Verschuren, F ;
Meyer, G ;
Obrosky, DS ;
Stone, RA ;
Cornuz, J ;
Fine, MJ .
EUROPEAN HEART JOURNAL, 2006, 27 (04) :476-481
[2]   The influence of extreme body weight on clinical outcome of patients with venous thromboembolism:: findings from a prospective registry (RIETE) [J].
Barba, R ;
Marco, J ;
Martín-Alvarez, H ;
Rondon, P ;
Fernández-Capitan, C ;
Garcia-Bragado, F ;
Monreal, M .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (05) :856-862
[3]   Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma [J].
Blackwell, K ;
Hurwitz, H ;
Liebérman, G ;
Novotny, W ;
Snyder, S ;
Dewhirst, M ;
Greenberg, C .
CANCER, 2004, 101 (01) :77-82
[4]  
BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1
[5]   The incidence and prognostic significance of elevated cardiac troponins in patients with submassive pulmonary embolism [J].
Douketis, JD ;
Leeuwenkamp, O ;
Grobara, P ;
Johnstonji, M ;
Söhne, M ;
Ten Wolde, M ;
Büller, H .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (03) :508-513
[6]   Prediction of pulmonary embolism extent by clinical findings, D-dimer level and deep vein thrombosis shown by ultrasound [J].
Galle, C ;
Papazyan, JP ;
Miron, MJ ;
Slosman, D ;
Bounameaux, H ;
Perrier, A .
THROMBOSIS AND HAEMOSTASIS, 2001, 86 (05) :1156-1160
[7]   Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) [J].
Goldhaber, SZ ;
Visani, L ;
De Rosa, M .
LANCET, 1999, 353 (9162) :1386-1389
[8]   Evalution and mangaement of the acutely dyspneic patient: the role of biomarkers [J].
Harrison, A ;
Amundson, S .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2005, 23 (03) :371-378
[9]   Predictors of survival after deep vein thrombosis and pulmonary embolism - A population-based, cohort study [J].
Heit, JA ;
Silverstein, MD ;
Mohr, DN ;
Petterson, TM ;
O'Fallon, WM ;
Melton, LJ .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (05) :445-453
[10]   Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism [J].
Kline, Jeffrey A. ;
Hernandez-Nino, Jackeline ;
Rose, Geoffrey A. ;
Norton, H. James ;
Camargo, Carlos A., Jr. .
CRITICAL CARE MEDICINE, 2006, 34 (11) :2773-2780